NO20060900L - Nitroosyderivater av Losartan, Valsartan, Candesartan, Telmisartan, Eprosartan og Olmesartan som angiotensin II-reseptorblokkere for behandling av kardiovaskulaer sykdom - Google Patents

Nitroosyderivater av Losartan, Valsartan, Candesartan, Telmisartan, Eprosartan og Olmesartan som angiotensin II-reseptorblokkere for behandling av kardiovaskulaer sykdom

Info

Publication number
NO20060900L
NO20060900L NO20060900A NO20060900A NO20060900L NO 20060900 L NO20060900 L NO 20060900L NO 20060900 A NO20060900 A NO 20060900A NO 20060900 A NO20060900 A NO 20060900A NO 20060900 L NO20060900 L NO 20060900L
Authority
NO
Norway
Prior art keywords
olmesartan
eprosartan
telmisartan
candesartan
valsartan
Prior art date
Application number
NO20060900A
Other languages
English (en)
Inventor
Piero Del Soldato
Ennio Ongini
Nicoletta Almirante
Original Assignee
Nicox Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox Sa filed Critical Nicox Sa
Publication of NO20060900L publication Critical patent/NO20060900L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Nifrooksyderivater av angiotensin Il-reseptorblokkere som Losartan, Valsartan, Candesartan, Telmisartan, Eprosartan, Olmesartan og beslektede forbindelser som har formel (I): R-(YON02)s hvor R og Y er som defmert i beskrivelsen.
NO20060900A 2003-07-31 2006-02-24 Nitroosyderivater av Losartan, Valsartan, Candesartan, Telmisartan, Eprosartan og Olmesartan som angiotensin II-reseptorblokkere for behandling av kardiovaskulaer sykdom NO20060900L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03102379 2003-07-31
PCT/EP2004/051550 WO2005011646A2 (en) 2003-07-31 2004-07-20 Nitrooxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-ii receptor blockers for the treatment of cardiovascular diseases

Publications (1)

Publication Number Publication Date
NO20060900L true NO20060900L (no) 2006-02-24

Family

ID=34112476

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060900A NO20060900L (no) 2003-07-31 2006-02-24 Nitroosyderivater av Losartan, Valsartan, Candesartan, Telmisartan, Eprosartan og Olmesartan som angiotensin II-reseptorblokkere for behandling av kardiovaskulaer sykdom

Country Status (29)

Country Link
US (1) US20060276523A1 (no)
EP (1) EP1653950B1 (no)
JP (1) JP2007500684A (no)
KR (1) KR20060056352A (no)
CN (1) CN100496490C (no)
AR (1) AR045145A1 (no)
AT (1) ATE383155T1 (no)
AU (1) AU2004260830B2 (no)
BR (1) BRPI0413028A (no)
CA (1) CA2534451A1 (no)
CY (1) CY1110447T1 (no)
DE (1) DE602004011230T2 (no)
DK (1) DK1653950T3 (no)
EC (1) ECSP066334A (no)
ES (1) ES2299861T3 (no)
HR (1) HRP20060084A2 (no)
IL (1) IL172703A0 (no)
IS (1) IS2534B (no)
MA (1) MA27987A1 (no)
MX (1) MXPA06001263A (no)
NO (1) NO20060900L (no)
NZ (1) NZ544463A (no)
PL (2) PL379420A1 (no)
PT (1) PT1653950E (no)
RU (1) RU2374240C2 (no)
SI (1) SI1653950T1 (no)
UA (1) UA87983C2 (no)
WO (1) WO2005011646A2 (no)
ZA (1) ZA200600856B (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1984871A (zh) 2004-07-20 2007-06-20 尼科克斯公司 制备硝基氧基酯、硝基氧基硫酯、硝基氧基碳酸酯和硝基氧基硫代碳酸酯的方法、用于所述方法的中间体及其制备
WO2006079610A1 (en) * 2005-01-31 2006-08-03 Nicox S.A. Nitrooxy sartan derivatives as angiotensin ii receptor blockers for the treatment of cardiovascular and inflammatory diseases
RU2306930C1 (ru) * 2005-12-28 2007-09-27 Михаил Владимирович Покровский Способ коррекции эндотелиальной дисфункции комбинацией лозартана и l-аргинина при l-name-индуцированном дефиците оксида азота
CN101024643A (zh) * 2006-02-20 2007-08-29 上海艾力斯医药科技有限公司 咪唑－5－羧酸类衍生物、制备方法及其应用
TW200821303A (en) * 2006-08-08 2008-05-16 Speedel Experimenta Ag Organic compounds
CA2668744C (en) 2006-11-17 2015-09-15 Queen's University At Kingston Compounds and methods for treating protein folding disorders
WO2008076245A2 (en) * 2006-12-13 2008-06-26 Merck & Co., Inc. Nitroderivatives as angiotensin ii receptor antagonists
JP5290190B2 (ja) 2006-12-06 2013-09-18 サルブリス・アセット・マネイジメント・カンパニー・リミテッド イミダゾール−５−カルボン酸誘導体の塩、製造方法及びその医薬組成物
TW200831079A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Angiotensin II receptor antagonists
CN101214242A (zh) * 2007-01-05 2008-07-09 上海艾力斯医药科技有限公司 新的药用组合物
EP1980559A1 (en) * 2007-04-10 2008-10-15 CTG Pharma S.r.l. Cardiovascular agents
CN101317842A (zh) 2007-06-07 2008-12-10 上海艾力斯医药科技有限公司 一种咪唑-5-羧酸衍生物的治疗用途
CN101407511B (zh) * 2007-10-11 2013-01-09 上海艾力斯生物医药有限公司 一种结晶型的咪唑-5-羧酸衍生物
AR069340A1 (es) 2007-11-26 2010-01-13 Merck & Co Inc Antagonistas del receptor de angiotensina ii
JP5570996B2 (ja) 2007-12-14 2014-08-13 エアロデザインズ インコーポレイテッド エアロゾル化可能な食料品の送達
AU2009206635A1 (en) * 2008-01-24 2009-07-30 Merck Sharp & Dohme Corp. Angiotensin II receptor antagonists
US8106034B2 (en) 2008-02-08 2012-01-31 Merck Sharp & Dohme Corp. Angiotensin II receptor antagonists
US20100311800A1 (en) * 2008-02-26 2010-12-09 Nicoletta Almirante Angiotensin ii receptor antagonists
US20110052674A1 (en) * 2008-02-26 2011-03-03 Merck Sharp & Dohme Corp. Angiotensin ii receptor blocker derivatives
AU2009246670A1 (en) * 2008-05-15 2009-11-19 Merck Sharp & Dohme Corp. Angiotensin II receptor antagonists
CN101596189A (zh) * 2008-06-05 2009-12-09 上海艾力斯生物医药有限公司 含有咪唑-5-羧酸类衍生物的药用组合物
US20110077279A1 (en) * 2008-06-09 2011-03-31 Nicoletta Almirante Angiotensin ii receptor antagonists
AR073259A1 (es) * 2008-07-29 2010-10-28 Merck & Co Inc Derivados de furosemida utiles como diureticos
WO2010015447A1 (en) * 2008-08-08 2010-02-11 Nicox S.A. Angiotensin ii receptor antagonists
EP2194048A1 (en) 2008-12-02 2010-06-09 Dirk Sartor Nitrate esters for the treatment of vascular and metabolic diseases
AR074425A1 (es) * 2008-12-05 2011-01-19 Merck Sharp & Dohme Derivados de nitrooxi como antagonistas del receptor de angiotensina ii.
AU2009338267B2 (en) 2009-01-23 2014-09-18 Hanmi Science Co., Ltd. Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
CA2796710A1 (en) 2010-04-19 2011-10-27 Cardiolynx Ag Valsartan derivatives carrying nitrogen oxide donors for the treatment of vascular and metabolic diseases
MX2012012225A (es) * 2010-04-23 2013-08-27 Piramal Entpr Ltd Profármacos de agentes tearapéuticos de liberación de óxido nítrico.
WO2011160974A2 (en) 2010-06-21 2011-12-29 Nicox S.A. Statin derivatives
JO3350B1 (ar) 2011-03-07 2019-03-13 Merck Sharp & Dohme مشتقات حلقية غير متجانسة محتوية على مجموعات أمينو أولية ومركبات داي أزينيومديولات
US9844599B2 (en) 2013-01-21 2017-12-19 Apparao Satyam Nitric oxide releasing produgs of therapeutic agents
CN103275074B (zh) * 2013-06-21 2016-08-10 黄冈鲁班药业股份有限公司 一种奥美沙坦衍生物及其制备方法
CN105820125B (zh) * 2015-01-09 2018-12-07 北京中医药大学 一种用于治疗高血压的化合物及其制备方法和用途
US10456405B2 (en) 2015-09-07 2019-10-29 Zhejiang Huahai Pharmaceutical Co., Ltd Nitric oxide-releasing prodrug molecule of substituted quinazolines
CN106800537B (zh) * 2017-01-18 2019-02-01 广东隆赋药业股份有限公司 丁苯酞-替米沙坦杂合物及其制备方法和用途
CN108892624B (zh) * 2018-06-20 2020-12-15 重庆威鹏药业有限公司 沙库巴曲硝基氧衍生物及其制备方法和应用
CN114105881B (zh) * 2020-08-31 2024-01-26 沈阳海诺威医药科技有限公司 血小板聚集抑制剂及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
ATE190051T1 (de) * 1989-06-14 2000-03-15 Smithkline Beecham Corp Imidazoalkensäure
WO1991000277A1 (en) * 1989-06-30 1991-01-10 E.I. Du Pont De Nemours And Company Substituted imidazoles
RU2067581C1 (ru) * 1989-06-30 1996-10-10 Е.И.Дюпон Де Немур Энд Компани Аралкилзамещенные имидазолы, обладающие противогипертоническим действием, способ их получения и фармацевтический состав, обладающий ингибирующей активностью в отношении ангиотензина ii
AT398202B (de) * 1991-10-04 1994-10-25 Chem Pharm Forsch Gmbh Neue imidazolderivate, verfahren zu ihrer herstellung und ihre verwendung
FR2725987B1 (fr) * 1994-10-19 1997-01-10 Sanofi Sa Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive
IT1311924B1 (it) * 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
WO2002015935A1 (fr) * 2000-08-25 2002-02-28 Takeda Chemical Industries, Ltd. Agents de reduction du fibrinogene
ITMI20011744A1 (it) * 2001-08-09 2003-02-09 Nicox Sa Farmaci per le vasculopatie

Also Published As

Publication number Publication date
KR20060056352A (ko) 2006-05-24
CN100496490C (zh) 2009-06-10
EP1653950A2 (en) 2006-05-10
ECSP066334A (es) 2006-07-28
IL172703A0 (en) 2006-04-10
EP1653950B1 (en) 2008-01-09
PT1653950E (pt) 2008-04-11
JP2007500684A (ja) 2007-01-18
UA87983C2 (ru) 2009-09-10
AU2004260830A1 (en) 2005-02-10
IS8332A (is) 2006-02-27
ZA200600856B (en) 2007-05-30
PL1653950T3 (pl) 2008-08-29
MA27987A1 (fr) 2006-07-03
IS2534B (is) 2009-08-15
MXPA06001263A (es) 2006-04-11
DE602004011230T2 (de) 2009-01-02
CA2534451A1 (en) 2005-02-10
DK1653950T3 (da) 2008-05-26
CY1110447T1 (el) 2015-04-29
AU2004260830B2 (en) 2010-04-29
ATE383155T1 (de) 2008-01-15
RU2006105804A (ru) 2007-09-20
WO2005011646A3 (en) 2005-04-21
WO2005011646A2 (en) 2005-02-10
SI1653950T1 (sl) 2008-06-30
CN1832742A (zh) 2006-09-13
NZ544463A (en) 2009-10-30
BRPI0413028A (pt) 2006-10-03
PL379420A1 (pl) 2006-09-04
ES2299861T3 (es) 2008-06-01
HRP20060084A2 (hr) 2006-04-30
AR045145A1 (es) 2005-10-19
US20060276523A1 (en) 2006-12-07
DE602004011230D1 (de) 2008-02-21
HK1095093A1 (zh) 2007-04-27
RU2374240C2 (ru) 2009-11-27

Similar Documents

Publication Publication Date Title
NO20060900L (no) Nitroosyderivater av Losartan, Valsartan, Candesartan, Telmisartan, Eprosartan og Olmesartan som angiotensin II-reseptorblokkere for behandling av kardiovaskulaer sykdom
NO20081476L (no) Substituerte benzimidazoler og fremgangsmater for fremstilling
NO20054407L (no) Cannabinoid reseptor ligander og deres anvendelser
NO20071254L (no) Fremgangsmate for fremstilling av irbesartan og mellomprodukter derav.
BRPI0605921A2 (pt) compostos orgánicos
RS20080510A (en) Benzimidazole derivative and use as angiotensin ii antagonist
IL208059A0 (en) Novel hsp90 inhibitory carbazole derivatives, compositions containing same and use thereof
ATE465163T1 (de) Heterocyclische verbindungen, ihre herstellung und ihre verwendung als antibakterielle mittel
ATE522523T1 (de) 1,3,5-trisubstituiertes triazolderivat
ZA200709240B (en) Solid forms of 1-(5-(IH-1,2,4-triazol-5-yl)(IH-indazol-3-yl)-3-(2-piperidylethoxy)benzene
DE602007009865D1 (de) 5-sulfanylmethylä1,2,4ütriazolä1,5-aüpyrimidin-7-olderivate als cxcr2-antagonisten
TN2010000045A1 (en) Novel herbicides
UY29709A1 (es) "compuestos quimicos"
CY1113320T1 (el) Σπειρο-κυκλικα νιτριλια ως αναστολεις πρωτεασης
BRPI0821357A2 (pt) derivados de oxadiazois de triazol
ATE538787T1 (de) Benzimidazol-derivative als raf-kinase-hemmer
NO20084543L (no) Benzimidazolderivater
ZA200800213B (en) Benzimidazole derivatives as 5-HT6, 5-HT24
MXPA05013149A (es) Derivados de imidazol como antagonistas del receptor de glutamato.
NO20070550L (no) Fremgangsmate for fremstilling av pyrrolotriazinforbindelser
NL1031384A1 (nl) Gesubstitueerde aryl-1,4-pyrazinederivaten.
WO2006069159A3 (en) Pharmaceutical compositions comprising amorphous benzimidazole compounds
WO2004075892A3 (en) Combination therapy for hypertension using lercanidipine and an angiotensin ii receptor blocker
UA92485C2 (ru) Производная бензамида и ее применение как антагониста ангиотензина ии
IL188273A (en) The process of producing benzimidazole compounds which includes one-stage cyclization

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application